Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (560)
  2. Solid Tumor Oncology Division (456)
  3. GSK Faculty (293)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (157)
  6. Hematologic Malignancies, Division of (155)
  7. Epidemiology and Biostatistics (152)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (120)
  10. Surgery (119)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (560)
  2. Solid Tumor Oncology Division (456)
  3. GSK Faculty (293)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (157)
  6. Hematologic Malignancies, Division of (155)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (25)

More People

Years
  1. 2025 (33)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (407)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    Messersmith, W.; Rasco, D.; De Bono, J.; Wang-Gillam, A.; Park, W.; Nickle, D.; Galkin, A.; Ferguson, B.; Carter, L.; Zhou, L.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • First-in-human phase 1/2a study of the novel nonfucosylated anti-CTLA-4 monoclonal antibody BMS-986218 +/- nivolumab in advanced solid tumors: Initial phase 1 results
    Meeting Abstract

    Friedman, C.; Ascierto, P.; Davar, D.; O'Hara, M.; Shapira-Frommer, R.; Dallos, M.; Khemka, V.; James, L.; Fischer, B.; Demes, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
    Meeting Abstract

    Sharma, M.; Dumbrava, E. I.; Carvajal, R.; Catenacci, D.; Emens, L.; Hanna, G.; Juric, D.; Kang, Y. K.; Lee, J.; Lee, K. W.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • CDX1140-01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (part 1) and in combination with CDX-301 (part 2) or pembrolizumab (part 3)
    Meeting Abstract

    Sanborn, R.; Hauke, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Bordoni, R.; Gordon, M.; Khalil, D.; Abdelrahim, M.; Marron, T.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Reveal: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: Local innate immune activation and systemic adaptive immune expansion for treating solid tumors
    Meeting Abstract

    Diab, A.; Curti, B.; Bilen, M.; Brohl, A.; Domingo-Musibay, E.; Borazanci, E.; Fanton, C.; Haglund, C.; Vimal, M.; Muhsin, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
    Meeting Abstract

    Lin, C. C.; Garralda, E.; Schoffski, P.; Hong, D.; Siu, L.; Martin, M.; Maur, M.; Hui, R.; Soo, R.; Chiu, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Preliminary results from Keynote-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors
    Meeting Abstract

    Bendell, J.; Messersmith, W.; Rasco, D.; Wang-Gillam, A.; Park, W.; Zhou, L.; Carter, L.; Bruey, J. M.; Li, J.; Ferguson, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 3 study (Cosmic-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
    Meeting Abstract

    Choueiri, T.; Albiges, L.; Powles, T.; Mohamed, N.; Wang, F.; Motzer, R.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Cohen, E.; Postow, M.; Sullivan, R.; Hong, D.; Yeckes-Rodin, H.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; Page, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Pai, S.; Adkins, D.; Wirth, L.; Chung, C.; Gibson, M.; Sukari, A.; Worden, F.; Colevas, D.; Saba, N.; Burtness, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save